Sionna Therapeutics reported a significant quarterly loss, exceeding analyst expectations due to substantial restructuring charges. These charges stemmed from a nearly 46% workforce reduction implemented in September, impacting both research and development and general administrative expenses. Despite the financial challenges, the company's cash reserves are projected to fund operations through the latter half of 2029. This extended runway supports the advancement of their SION-451 plus SION-2222 combination therapy into a Phase 2 trial in early 2027. The company's focus remains on this dual combination for cystic fibrosis, following the discontinuation of a previous program.
Boston, MA
https://247wallst.com/cards/sionna-therapeutics-q3-2026-earnings-sion-01m72nz25ynxya4d40k65yhvqq